TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05121987

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane block
Description: An ultrasound linear probe is going to be placed in a longitudinal orientation 3 cm lateral to the T6 spinous process corresponding to the T5 transverse process. . Local infiltration with 2% of lignocaine at the site of needle insertion is going to be administered. Using in plane approach an 18 G Tuohy needle will be inserted in caudal-cephalad direction, until the tip is deep to erector spinae muscle, as evidenced by visible hydro-dissection below the muscle plane, and on injection of 5 ml of normal saline.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Wound Infusion
Description: Towards the end of surgery, a multiholed 15-cm Anesthesia catheter will be placed in the preperitoneal space (the subfascial space between the peritoneum and posterior fascia) under direct vision and to be tunneled via the rectus sheath to the skin, rolled out and exiting laterally and stabilized with an adhesive tape on skin.
Study: NCT06186453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Father-Preterm Newborn Bonding Program
Description: B-PreBAP will be applied to the fathers in the intervention group. B-PreBAP application will consist of two stages. The first stage will be passive participation and the second stage will be active participation. B-PreBAP will be applied to fathers for a total of two weeks (Heo \& Oh, 2019). In order to prevent interaction between the fathers in the intervention group and the fathers in the control group, the intervention will not be carried out during the routine visiting and information hours of the NICU (13:30-14:30 on Mondays, Wednesdays and Fridays). In the first two interviews, NICU introduction and B-PreBAP education about preterm newborns will be given. In the last three interviews, fathers will be involved in one-to-one practices with their preterm newborns.
Study: NCT06475573

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary fiber probiotic beverages
Description: The intervention period lasted for 8 weeks. During this time, Participants received dietary guidance from researchers. The target energy intake was based on the limited energy diet model recommended in the Chinese Guidelines for Medical Nutrition Therapy of Overweight/Obesity (2021). Carbohydrates were to account for 55%-60% and fat for 25%-30% of total daily energy intake. Participants in experimental group consumed two 35g sachets of fermented dietary fiber probiotic solid beverages daily, replacing part of the staple food for lunch and dinner.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: whole grain porridge
Description: The intervention period lasted for 8 weeks. During this time, Participants received dietary guidance from researchers. The target energy intake was based on the limited energy diet model recommended in the Chinese Guidelines for Medical Nutrition Therapy of Overweight/Obesity (2021).Participants in control group consumed two 35g sachets of convenient whole grain porridge daily, replacing part of the staple food for lunch and dinner.
Study: NCT05373953

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF6001
Description: CHF6001 will be administered using the NEXThaler® DPI device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6001
Description: CHF6001 will be administered using the NEXThaler® DPI device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6001
Description: CHF6001 will be administered using the NEXThaler® DPI device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6001
Description: CHF6001 will be administered using the NEXThaler® DPI device
Study: NCT06310057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib (JAKi) is a targeted therapy option for patients with refractory ax-SpA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib (JAKi) is a targeted therapy option for patients with refractory ax-SpA.
Study: NCT05940220

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Acetazolamide placebo add-on a standard therapy of iv furosemide in one day and oral furosemide during three consecutive days will be used for the comparator arm

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT05503654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education
Description: Those interventional groups will take nutrition education by Gada System leaders for 6 consecutive months
Study: NCT04251260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positioning in flexion
Description: The intervention group will be positioned in flexion (i.e. lower limbs in flexion, hand in midline) with an aid, the Snuggle up (Philips, USA). With positioning, the neonates bottom is tucked down in the snuggle up pocket, legs are aligned and gently flexed and hands towards midline and near the face.~Positioning will be demonstrated to the nursing staff of the Neonatal Intensive Care Unit (NICU). The intervention group will receive positioning during day and night throughout the intervention period.
Study: NCT04716530

Intervention type: OTHER
Intervention: No intervention is associated with the study.
Description: No intervention is associated with the study.

Intervention type: OTHER
Intervention: No intervention is associated with the study.
Description: No intervention is associated with the study.

Intervention type: OTHER
Intervention: No intervention is associated with the study.
Description: No intervention is associated with the study.
Study: NCT06143306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine.
Description: an ultrasound guided pectoserratus block with 25 mL of 0.25% bupivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: an ultrasound guided pectoserratus block with 25 mL of saline
Study: NCT04854629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinomed active
Description: Wearing of the orthosis 2-3 h/twice a day for 16 weeks Supplementation of a maximum of 1000 mg/d calcium and 800 IE/d vitamin D
Study: NCT04500756

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Smaller studies have suggested that metformin may reduce the rate at which aortic aneurysms enlarge. This study will test this question: does metformin prevent AAAs from growing larger?

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One group will be randomized to receive the study drug Metformin and the other group will receive a placebo
Study: NCT01278251

Intervention type: PROCEDURE
Intervention: Distal Biceps Re-Insertion
Study: NCT06531161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suxiao Jiuxin Pill
Description: Suxiao Jiuxin Pill is a traditional Chinese medicine compound composed of Ligusticum Wallichii and Borneo Camphorwood, and its clinical safety has been confirmed. Traditional Chinese medicine theory believes that Suxiao Jiuxin Pill has the effects of promoting qi and blood circulation, removing blood stasis and relieving pain, which may help alleviate symptoms of AMS.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is made of less than 10% of the amount of Suxiao Jiuxin Pill, with similar dosage, odor, and taste.
Study: NCT04945590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Intervention Program
Description: Four separate virtual individual and group interviews (via telephone or online), which will be scheduled with the help of champions and leaders of the Latino community who will collaborate as companions to improve the commitment and experience of families.
Study: NCT05777096

Intervention type: DIAGNOSTIC_TEST
Intervention: Standardised Nordic questionnaires
Description: participants will complete the SNQ online. Estimated time of participation per person: 15 minutes to fill in the questionnaires
Study: NCT04727879

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Synovial membrane biopsy with puncture of synovial fluid
Description: The biopsy of the shoulder bursae will be carried out thanks to a device Tru-cut (Tru-Cut Biopsy Needle), minimally invasive, introduced, as during an infiltration, within the bursa serosa.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Synovial membrane biopsy with puncture of synovial fluid
Description: The biopsy of the shoulder bursae will be carried out thanks to a device Tru-cut (Tru-Cut Biopsy Needle), minimally invasive, introduced, as during an infiltration, within the bursa serosa.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Joint fluid sampling
Description: In case of associated peripheric arthritis, the patient will also be offered a sample of joint fluid during a cortisonic infiltration for analgesic purposes, performed as part of routine care.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample
Description: A blood sample taken during routine care and unused will also be collected from patients and controls for immunoassays.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample
Description: A blood sample taken during routine care and unused will also be collected from patients and controls for immunoassays.
Study: NCT05815290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Cadonilimab 10mg/kg iv on day 1 for every 21 days with a total of 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Cadonilimab 10mg/kg iv on day 1 for every 21 days with a total of 8 cycles
Study: NCT05149365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin + Standard Prophylaxis
Description: Sitagliptin 600 mg ever 12 hours orally will be given starting from the day before transplantation through day +14 after transplantation and Standard prophylaxis regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Prophylaxis
Description: Standard prophylaxis regimen for GVHD of Alternative Donor HSCT, include Cyclosporine (CsA),Methotrexate (MTX), Mycopherol ester (MMF) and Antithymic Globulin
Study: NCT05329545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upifitimab rilsodotin
Description: Upifitimab rilsodotin will be administered once every four weeks until completion, disease progression, unacceptable toxicity, voluntary discontinuation, or death (approximately up to 18 months).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo controlled arm.
Study: NCT05821231

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SBRT + MEDI5752
Description: SBRT (5 fractions of 10 Gy every two or three days) will be delivered to one lung metastasis (12 days maximum) in combination with MEDI5752\* administered intravenously.~The first dose of MEDI5752 will be administered on the day of the last SBRT fraction, then every 3 weeks for up to a maximum of 12 months.~\* Dosing 500 mg or 750 mg, according to the recommended dose determined during the dose exploration phase
Study: NCT04771468

Intervention type: DEVICE
Intervention: MOSTCAREup Monitoring
Description: The patients will be equipped with mini-invasive hemodynamic monitoring (the MOSTACAREup system). The MOSTCAREup obtains the hemodynamic data from either the same arterial femoral line used by the neuro-radiologist to perform the treatment or from a dedicated radial artery, as decided by the attending anesthetist to monitor and optimize arterial pressure (the decision to use the arterial line is at discretion of the attending anesthetist for clinical reasons and does not delay the procedure, which starts using always the femoral access).

Intervention type: DEVICE
Intervention: Ecocardiography
Description: Echocardiography will be performed 1) soon after the end of the treatment (whenever possible, avoiding delays, before od during the treatment in the angiography room); 2) at day 1 after the procedure; 3) at day 3 after the procedure.
Study: NCT05622851

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane Contour
Description: Hyaluronic Acid dermal filler

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvederm Voluma
Description: Hyaluronic Acid dermal filler
Study: NCT06011174

Intervention type: OTHER
Intervention: survey application
Description: Participants will only be asked to fill out the questionnaires.
Study: NCT04578613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-022
Description: ICP-022 at a dose of 150mg, QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorambucil
Description: 0.5 mg/kg body weight orally on Day 1 and Day 15 of Cycles 1-6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m2 IV infusion on Day 1 of Cycle 1. 500 mg/m2 IV infusion on Day 1 for each of subsequent cycles (Cycles 2-6)
Study: NCT06323018

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Preconditioning
Description: 4 cycles of 5 min pressure (produces an ischemia episode in subject's upper limb) with AutoRIC device (Starfish Medical, Canada)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: 4 cycles of 5min light pressure (no ischemia produced) with AutoRIC device (Starfish Medical, Canada) to imitate the RIPC procedure
Study: NCT04734327

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthokine periradicular injection
Description: Ultrasound guided injections

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orthokine epidural injection
Description: Ultrasound guided injections
Study: NCT05900960

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tea
Description: Orally administered. Decaffeinated tea, with no additives (sugar, honey, etc.)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tea
Description: Orally administered. Decaffeinated tea, with no additives (sugar, honey, etc.)
Study: NCT05311488

Intervention type: DIAGNOSTIC_TEST
Intervention: neurofilament light chain
Description: Blood test

Intervention type: DIAGNOSTIC_TEST
Intervention: neurofilament light chain
Description: Blood test

Intervention type: DIAGNOSTIC_TEST
Intervention: neurofilament light chain
Description: Blood test
Study: NCT05384262

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD0780
Description: Subjects will receive AZD0780 orally as a single ascending dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD0780
Description: Subjects will receive AZD0780 orally as a single ascending dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD0780
Description: Subjects will receive AZD0780 orally as a single ascending dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD0780
Description: Subjects will receive AZD0780 orally as a single ascending dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD0780
Description: Subjects will receive AZD0780 orally as a single ascending dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD0780
Description: Subjects will receive AZD0780 orally as a single ascending dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD0780
Description: Subjects will receive AZD0780 orally as a multiple ascending dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD0780
Description: Subjects will receive AZD0780 orally as a multiple ascending dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD0780
Description: Subjects will receive AZD0780 orally as a multiple ascending dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD0780
Description: Subjects will receive AZD0780 orally as a multiple ascending dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD0780
Description: Subjects will receive AZD0780 orally as a multiple ascending dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD0780
Description: Subjects will receive AZD0780 orally as a single and multiple ascending dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD0780
Description: Subjects will receive AZD0780 orally as a single and multiple ascending dose.
Study: NCT05311488

Intervention type: DIAGNOSTIC_TEST
Intervention: In-vivo Meissner Corpuscle imaging
Description: Imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: In-vivo Meissner Corpuscle imaging
Description: Imaging
Study: NCT05384262

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo matching the AZD0780 dose orally as a single ascending dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo matching the AZD0780 dose orally as a single ascending dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo matching the AZD0780 dose orally as a single ascending dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo matching the AZD0780 dose orally as a single ascending dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo matching the AZD0780 dose orally as a single ascending dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo matching the AZD0780 dose orally as a single ascending dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo matching the AZD0780 dose orally as a multiple ascending dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo matching the AZD0780 dose orally as a multiple ascending dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo matching the AZD0780 dose orally as a multiple ascending dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo matching the AZD0780 dose orally as a multiple ascending dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo matching the AZD0780 dose orally as a multiple ascending dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo matching the AZD0780 dose orally as a single and multiple ascending dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo matching the AZD0780 dose orally as a single and multiple ascending dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Subjects will receive rosuvastatin orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Subjects will receive rosuvastatin orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Subjects will receive rosuvastatin orally.
Study: NCT05053438

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Multidisciplinary Feeding Intervention (IMFI)-Standard of Care
Description: Standard care involves behavioral intervention delivered during admission Intensive Multidisciplinary Intervention. Patients admitted to the program will participate in four therapeutic meals per day, five days per week (Monday through Friday). The behavioral intervention involves a standard sequence of reinforcement techniques, bite persistence (a.k.a., contingency contacting, escape extinction), and stimulus fading/antecedent manipulation protocols. Parent training will be the central method for structuring meals and transferring treatment gains from the clinic to the home setting. The sequence and steps for parents training will follow a sequential, proficiency-based process, with caregivers transitioning to serve as the primary feeder by discharge.~Management of tube wean in our standard of care involves reducing tube feeding calories based on oral intake at a 1:1 ratio.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Multidisciplinary Feeding Intervention (IMFI) standard of care + rapid tube weaning
Description: The experimental arm combines standard care with a rapid tube wean. On day 1, the dietitian will meet with the caregiver to determine the usual tube feeding schedule. The dietitian will then create a tube feeding plan that meets 70% of the child's caloric needs (a 30% reduction).On day 3, if a patient has moved past a rice size bite volume in therapeutic meals, the patient's tube feedings will be further reduced to meet 50% of needs. All schedules and documents will be updated accordingly. After the 50% tube wean cut, the dietitian will use a regular tube wean sheet to provide credit for oral intake for the remainder of admission.
Study: NCT04483245

Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: Blood sampling

Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: Blood sampling

Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: Blood sampling

Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: Blood sampling

Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: Blood sampling
Study: NCT05507918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral water and clear liquids
Description: Measured oral intake of fluids prior to tonsillectomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral water and clear liquids
Description: Measured oral intake of fluids prior to tonsillectomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral water and clear liquids
Description: Measured oral intake of fluids prior to tonsillectomy
Study: NCT04291599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Subjects will be randomized to either receive opioid (standard of care) or opioid-sparing analgesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid
Description: Subjects will be randomized to either receive opioid (standard of care) or opioid-sparing analgesia
Study: NCT05123963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: 3 times per week high-intensity interval training (HIIT) on a cycle ergometer for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity interval training
Description: 3 times per week high-intensity interval training (HIIT) on a cycle ergometer for 12 weeks.
Study: NCT04787250

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Phage Therapy
Description: Phage will be administered based on patient's matching results.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two-Stage Exchange Arthroplasty
Description: Performed per the study center's standard of care. No investigational products are used.
Study: NCT05612763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self fitting hearing device
Description: comparison of outcomes when device is fit by clinician or self fit